Schering Deutschland GmbH

euro adhoc: Schering AG
other
Planned interim analysis of CONFIRM 2 trial of PTK/ZK indicates low probability of demonstrating overall survival benefit in second-line therapy of metastatic colorectal cancer

-------------------------------------------------------------------------------- Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. -------------------------------------------------------------------------------- 28.07.2005 Schering AG announced today the disclosure data from the CONFIRM 2 trial with PTK/ZK in the second-line treatment of metastatic colorectal cancer (mCRC). This decision was based on information obtained after trading hours on July 27, 2005 and included a review by the independent Data Safety Monitoring Board (DSMB) showing a low probability of demonstrating an improvement in overall survival at final analysis. The DSMB assessment was based on a planned interim analysis. Progression free survival (PFS), a secondary endpoint of the study, was improved in favor of the PTK/ZK treatment arm with greater effect observed in the pre-defined patient sub-group with high Lactate dehydrogenase (LDH) levels consistent with findings previously seen in CONFIRM 1. In light of these findings the regulatory filing strategy and timelines will be reviewed. Further results of CONFIRM 2 are expected in mid-2006. The decision to disclose the CONFIRM 2 data does not impact the other ongoing Phase III trial, CONFIRM 1, which will continue as planned with final overall survival results expected in the second half of 2006. end of announcement euro adhoc 28.07.2005 07:00:00 -------------------------------------------------------------------------------- ots Originaltext: Schering Deutschland GmbH Im Internet recherchierbar: http://www.presseportal.de Further inquiry note: Oliver Renner Head Corporate Business Communication Tel.: +49 (0)30 468 12431 Fax: +49 (0)30 468 16646 E-Mail: oliver.renner@schering.de Branche: Pharmaceuticals ISIN: DE0007172009 WKN: 717200 Börsen: Baden-Württembergische Wertpapierbörse SWX Swiss Exchange Niedersächsische Börse zu Hannover New York Berliner Wertpapierbörse Hamburger Wertpapierbörse Frankfurter Wertpapierbörse Börse Düsseldorf Bayerische Börse Bremer Wertpapierbörse (BWB)

Das könnte Sie auch interessieren: